Drug intelligence / Profile preview

acellular pertussis vaccine + whole-cell pertussis vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Acellular pertussis vaccine + whole-cell pertussis vaccine refers to the use or co-administration of both acellular (aP) and whole-cell (wP) formulations of the pertussis (whooping cough) vaccine. Both vaccines are designed to protect against infection by Bordetella pertussis, but differ in composition and safety profile. The whole-cell vaccine contains inactivated entire B. pertussis organisms, while the acellular version contains purified components such as inactivated pertussis toxin, filamentous hemagglutinin, fimbrial antigens, and/or pertactin[3][4]. Whole-cell vaccines are effective but associated with more frequent adverse reactions; acellular vaccines were developed to reduce these side effects while maintaining efficacy[1][3][4]. Both types induce immunity by stimulating an immune response against B. pertussis antigens.

02

Targets

FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)Fim2 (Bordetella pertussis fimbrial protein 2)Fimbrial antigen type 3

Beyond the preview

Go deeper on acellular pertussis vaccine + whole-cell pertussis vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acellular pertussis vaccine + whole-cell pertussis vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call